Safety and immunogenicity of Anti PD-L1 (Atezolizumab) given as an immune primer or concurrently with extended field chemoradiotherapy for node positive locally advanced cervical cancer: an NRG Oncology trial (024)

Jyoti Mayadev, Dmitriy Zamarin, Wei Deng, Heather A. Lankes, Giulio Pesci, Kay J. Park, Barbara L. Banbury, Ned Sherry, Sharad Ghamande, Laura L. Holman, Cara Mathews, Roisin E. O’Cearbhaill, Carol Aghajanian, Russell J. Schilder